HSD17B11 is a short-chain dehydrogenase/reductase enzyme that plays multifaceted roles in cellular metabolism and pathology. Its primary function involves androgen metabolism, catalyzing the oxidation of androstan-3α,17β-diol to androsterone and showing limited activity toward testosterone 1. The enzyme's mechanism of action extends beyond steroid metabolism to include lipid homeostasis regulation, where it associates with lipid droplets and controls hepatocellular lipid content through interactions with GCKIII kinases 2. HSD17B11 also bioactivates cytotoxic alkynylcarbinols by oxidizing them to protein-reactive electrophiles, leading to endoplasmic reticulum stress and apoptosis 3. Regarding disease relevance, HSD17B11 expression is dysregulated in multiple cancers. It is upregulated in pancreatic cancer and serves as a prognostic marker 4, while downregulation in lung adenocarcinoma correlates with poor overall survival 5. In esophageal cancer, HSD17B11 is regulated by m6A demethylase FTO and promotes lipid droplet formation 6. Clinically, the enzyme shows promise as both a biomarker and therapeutic target, with genome-wide association studies identifying it as a locus associated with lean body mass 7. Its transcriptional regulation by Sp1 and C/EBPα in prostate cancer cells suggests tissue-specific regulatory mechanisms 1.